Understanding metabolism related differences in ocular efficacy of MGV354

Abstract

1. MGV354 was being developed as a novel ocular therapy for lowering of intraocular pressure, a key modifiable risk factor for glaucoma. MGV354 is an activator of soluble guanylate cyclase, an enzyme known to be involved in the regulation of IOP. MGV354 has been shown to robustly lower IOP over 24 h after a single topical ocular drop in rabbit and monkey pharmacology models. However, MGV354 failed to produce similar results in patients with ocular hypertension or open-angle glaucoma.

2. With an objective of explaining the lack of efficacy in the clinic, we attempted to study whether human metabolism was significantly different from animal metabolism. The present study documents the investigation of metabolism of MGV354 in an effort to understand potential differences in biotransformation pathways of MGV354 in rabbits, monkeys, and humans.

3. Overall twenty-six metabolites, formed via oxidative and conjugative pathways, were identified in vitro and in vivo. In vitro hepatic metabolism was qualitatively similar across species, with minor but distinct differences. There were no observable interspecies differences in the hepatic and ocular metabolism of MGV354. Although ocular metabolism was not as extensive as hepatic, the results do not explain the lack of efficacy of MGV354 in clinical studies.

Keywords:

• MGV354
• ocular metabolism
• ocular hypertension
• intraocular pressure
• biotransformation

Acknowledgments

The authors thank Doug Bevan, Rebecca Stacy, Nan Ji, Ann Brown, Su Huskey, and Jim Mangold for their contributions to the project. Helpful discussions with Gian Camenisch, Markus Walles, and Mithat Gunduz are also acknowledged.

Disclosure statement

The authors report no conflict of interest.